DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

Dentsply Sirona has demonstrated robust sales growth, with reported sales in Europe increasing by 9.9% and showing a 2.6% growth on a constant currency basis, indicating strong market demand in that region. The company's Wellspect Healthcare division has notably contributed to its positive outlook, generating $83 million in revenue with a remarkable 15.6% increase and maintaining attractive operating margins exceeding 30%. Additionally, expectations of continued improvement in operating expenses as a percentage of revenue suggest a potential for enhanced profitability moving forward, further reinforcing the positive financial outlook for Dentsply Sirona.

Dentsply Sirona has revised its sales expectations, now projecting a decrease of 4% to 5% in constant currency sales, a notable shift from earlier forecasts of a 2% to 4% decline. The company anticipates a decline in its GAAP gross margin by 160 basis points for Q3/25 compared to the same period in 2024, along with a reduced adjusted EBITDA margin expectation for FY/25, falling from over 19% to over 18%. Additionally, significant challenges are highlighted in the orthodontics and implants segment, primarily attributed to adverse impacts from the shutdown of the Byte business, leading to a projected revenue decline of 15% in that area.